Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · IEX Real-Time Price · USD
39.41
+0.42 (1.08%)
May 17, 2024, 4:00 PM EDT - Market closed
Revolution Medicines Revenue
Revolution Medicines had revenue of $4.57M in the twelve months ending March 31, 2024, down -86.89% year-over-year. In the year 2023, Revolution Medicines had annual revenue of $11.58M, a decrease of -67.27%.
Revenue (ttm)
$4.57M
Revenue Growth
-86.89%
P/S Ratio
1,416.44
Revenue / Employee
$12,079
Employees
378
Market Cap
6.47B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
Dec 31, 2018 | 20.17M | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.32B |
DENTSPLY SIRONA | 3.94B |
The Ensign Group | 3.85B |
Acadia Healthcare Company | 2.99B |
Masimo | 1.98B |
Exelixis | 1.85B |
HealthEquity | 999.59M |
Halozyme Therapeutics | 862.99M |
RVMD News
- 10 days ago - Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 17 days ago - Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 - GlobeNewsWire
- 5 weeks ago - Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins - GlobeNewsWire
- 5 weeks ago - Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins - GlobeNewsWire
- 6 weeks ago - Revolution Medicines to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 3 months ago - Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 - GlobeNewsWire